Introduction {#s0005}
============

The loss of retinal neurons, their connections and supporting glia in ocular degenerative diseases causes permanent blindness, principally because lost photoreceptors and retinal ganglion cells (RGCs) are not replaced and RGC axons fail to regenerate ([@bb0065]). Clinically, there are neither neuroprotective nor axogenic therapies available that restore lost visual system connectivity in retinal degenerative disease and translatable techniques for the replacement of lost RGC and photoreceptors are in their infancy. The retina is classified as central nervous system (CNS) tissue and the characteristics of its regenerative response are shared by other CNS tissues, including the brain and spinal cord.

Stem cell treatments developed as therapies for retinal degeneration fall into two broad categories: stem cells from (1), sources exogenous to the retina including mesenchymal stem cells (MSC) neural stem cells (NSCs) and embryonic/induced pluripotent stem cells (ESCs/iPSCs); and (2), endogenous retinal stem cells such as Müller glia ([@bb0535; @bb0600]), ciliary epithelia-derived stem cells ([@bb0015; @bb0695]) and retinal pigment epithelial (RPE) stem cells.

Potential non-retinal-derived adult stem cell based strategies being developed to treat retinal degeneration include NSC ([@bb0465; @bb0420]) and MSC derived from either bone marrow (BMSC) ([@bb0770; @bb0285; @bb0390]), adipose tissues (ADSC) ([@bb0700]) or dental pulp (DPSC) ([@bb0470]). MSC predominantly provide trophic support for the neuroprotection and axon regeneration of damaged retinal cells either directly through the secretion of neurotrophic factors (NTFs) ([@bb0285; @bb0290; @bb0470]) or possibly indirectly after stimulation of endogenous retinal cells ([@bb0380]) which, when activated, could provide additional paracrine support and/or effect cell replacement. There is no evidence that ESCs/iPSCs provide substantial paracrine support, but they do seem to be able to replace degenerating photoreceptors and RPE cells ([@bb0100; @bb0355]). NSCs directly differentiate into neural and glial phenotypes after transplantation into spinal cord injury (SCI) and traumatic brain injury (TBI) sites ([@bb0270; @bb0440]). They also secrete trophic factors ([@bb0435]) and, although limited work has been performed in the eye with NSC, may have potential for both the neuroprotection and replacement of retinal neurons, including RGC. The differential efficiency of NSC/MSC/ESC/iPSC to perform these disparate tasks is the key to identifying the phenotype most fitted to provide the optimal safe therapy for retinal disease.

Of the endogenous retinal stem cells, Müller glia have been induced to dedifferentiate into retinal progenitors which can then transform into multiple retinal phenotypes including photoreceptors in the photoreceptor-damaged eye ([@bb0555; @bb0405]). Ciliary epithelial-derived stem cells are self-renewing, multipotential retinal progenitor cells found in the pigmented ciliary epithelium of the retina ([@bb0750]), some of which differentiate in vitro into rhodopsin^+^ photoreceptors ([@bb0045; @bb0135; @bb0160]). The RPE layer generates new retina in some animals ([@bb0190]) and, in humans, contains a small population of stem cells that can mature into new RPE cells as well as cells with a neuronal phenotype ([@bb0625]). Whilst manipulation ([@bb0765]) and transplantation ([@bb0105; @bb0085]) of endogenous retinal stem cells have the potential to treat retinal degeneration, their mechanism of action is largely restricted to RPE and photoreceptor replacement with RGC replacement proving more refractory to such strategies.

There are currently many clinical trials ongoing which aim to test the safety and efficacy of stem cell transplantation in the eye ([Table 1](#t0005){ref-type="table"}). This review focuses on the potential of non retinal-derived stem cells, in particular NSC, BMSC, ADSC, DPSC and ESC/iPSC for the treatment of traumatic and degenerative eye disease and, where relevant, inter-relates some findings from stem cell research in the spinal cord and brain. Much overlap exists regarding the mechanisms and efficacy of ESC and iPSC and is therefore discussed together, readers are directed towards the following reviews for specific discussion on ESC ([@bb0805]) and iPSC ([@bb0745]) for the treatment of the retina. Readers are also referred to the following articles discussing treatments using MSC not discussed in this review, such as umbilical blood-derived MSC ([@bb0790; @bb0115]), as well as endogenous retinal stem cells ([@bb0765]).

Ntf-mediated effects of stem cells {#s0010}
==================================

Retinal cell degeneration {#s0050}
-------------------------

The extensive literature on NTF-mediated neuroprotection has been reviewed by [@bb0055], [@bb0665], [@bb0295] and [@bb0505]. After uptake by axons innervating distant neuronal targets, NTFs are retrogradely transported to somata ([@bb0155]) where they are neuroprotective. During development, neurons that fail to innervate their targets are starved of these survival signals and die by apoptosis ([@bb0080]). Many adult axotomised neurons also atrophy and die after disconnection from target-derived NTF, but the viability of neurons with collaterals proximal to the transection site is protected by a supply of NTF from spared innervated targets and from local glia ([@bb0170; @bb0185]). Since axon collaterals are absent in the optic nerve, RGCs are exquisitely sensitive to optic nerve damage, so that approximately 40% die within 7 days ([@bb0020]) and 90% are lost by 14--21 days ([@bb0490; @bb0060]). RGC loss detailed above is of relevance to diseases such as glaucoma and traumatic optic neuropathy.

The failure of adult CNS neurons to regenerate damaged axons is attributed to suppression of intrinsic axogenic machinery, the paucity of NTF essential for axon growth cone advance ([@bb0065]) and the presence of axon growth inhibitory factors ([@bb0610; @bb0630]) mediating growth cone collapse although the relative importance of these differing factors is debatable. The neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) phosphorylate tyrosine residues ([@bb0155]) after binding to the tropomyosin related kinase (TrK) receptor and promote RGC survival and axon growth ([@bb0065]) by activating intracellular signalling pathways (MAPK/PI3K/PKC; [Fig. 1](#f0005){ref-type="fig"}), whilst ciliary neurotrophic factor (CNTF) activates the JAK pathway after binding to the heterotrimeric gp130 receptor complex and signal through phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) to activate the serine--threonine kinase mammalian target of rapamycin (mTOR), to promote axogenic protein synthesis and inhibit glycogen synthase kinase-3β (GSK3β) which, amongst other roles, regulates growth cone dynamics ([@bb0505]). Experimental activation of mTOR signalling in adult mice promotes RGC survival and axon regeneration after optic nerve transection ([@bb0565; @bb0505]). Promoting axon regeneration is relevant to scenarios in which either the optic nerve is injured, or RGCs are transplanted into the ganglion cell layer ([@bb0245]) which subsequently require long distance regeneration of their axons.

Photoreceptor outer segments are damaged by light and approximately 10% of the outer segments are recycled by RPE-mediated phagocytosis each day. The digestion of internalised phagosomes is not 100% efficient and toxic lysosomal proteins such as lipofuscin, build up leading to RPE degeneration ([@bb0070]). The thickening of the outer limiting membrane and successive reduction in the supply of diffusible factors to the RPE also contribute to the degeneration. The subsequent failure in photoreceptor outer segment phagocytosis by the degenerating RPE is the primary pathology in age related macular degeneration (AMD) and retinitis pigmentosa ([@bb0070]).

NTF treatment strategies {#s0055}
------------------------

Treatments for long term RGC neuroprotection and axon regeneration are limited and delivery of individual NTF promotes incomplete and unsustained axon regeneration in the transected rat optic nerve ([@bb0410]) and spinal cord ([@bb0445]). For example, intravitreal (*ivit*) injection of recombinant BDNF and CNTF rescues axotomised RGC from death for up to 7 days ([@bb0490; @bb0020]). Long term trophic support requires repeated low dose NTF injections ([@bb0335; @bb0340]) since transient high peak bolus delivery of NTF down-regulates TrK receptors ([@bb0810; @bb0110]). Injectable hydrogel formulations composed of collagen, alginate or chitosan are being developed ([@bb0560]) that continuously and slowly release low titres of NTF in vivo over several weeks. However, drug loading of hydrogels is limited and thus, for chronic neurodegenerative diseases like glaucoma, sustained delivery requires repeated hydrogel implantation, making FDA approval a significant challenge. Alternative treatments, such as the transplantation of cells with extended longevity engineered to continuously produce low levels of specific NTF combinations, remove the need for repeated injections and overcome the problems with bolus NTF delivery regimes. For example, *ivit* transplantation of genetically engineered fibroblasts that overexpress fibroblast growth factor-2 (FGF-2), NT-3 and BDNF significantly increases RGC survival and axon regeneration after optic nerve crush ([@bb0410]).

Stem cells and NTF treatment {#s0060}
----------------------------

Stem cells, transfected with *ntf* genes or induced to secrete NTF using epidermal growth factor (EGF)/FGF have been grafted into the retina to treat retinal degeneration e.g. : (1), BMSC secreting BDNF, glial cell line-derived neurotrophic factor (GDNF) and neurotrophin-4 are RGC neuroprotective and improve visual function in cases of traumatic optic neuropathy ([@bb0390]), sodium iodate-induced damage of the retina ([@bb0450]) and chronic ocular hypertension ([@bb0235]); (2), NSCs engineered to secrete CNTF attenuate photoreceptor death in mouse models of retinitis pigmentosa ([@bb0300]); (3), ESC-derived neural progenitor cells transfected with crystallin-β-b2 promote both RGC and photoreceptor survival ([@bb0075]); and (4), a glucagon-like peptide-1-secreting cell line promotes RGC survival after optic nerve crush ([@bb0775]). Despite possible adverse effects, cell transplantation "mono-therapies" offer the potential advantages of continuous secretion of multiple NTFs for the duration of the viability of the transplant. In the eye, BMSC/ADSC/DPSC survive for at least 3 to 5 weeks ([@bb0285; @bb0390; @bb0225; @bb0470]) and *ivit* delivery of cell suspensions and transplantation of a retrievable permeable capsule loaded with stem cells ([@bb0775]) are also viable options for patients with retinal degenerative disease ([@bb0645]).

Ivit/subretinal stem cell implantation {#s0015}
======================================

The fate of transplanted stem cells in the eye remains undetermined and thus the incidence of immune rejection, differentiation into unpredicted phenotypes and unbridled migration within CNS neuropil, together with possible oncogenesis, all remain poorly defined. Safeguards against these outcomes include encapsulation of the stem implant ([@bb0775]) and genetic modification so that the cells carry inducible suicide genes, such as viral-derived thymidine kinase allowing selective destruction of the transplanted cells when treated with the toxic drug ganciclovir ([@bb0775]). However, the potential risks of transplanting stem cells in the eye may have been exaggerated where cell movement is restrained and immune reactions muted. For example, after *ivit* injection, MSC cluster in the vitreous body ([@bb0285; @bb0225; @bb0470; @bb0485]), although a small number do migrate into the retina they are neither tumorigenic nor exhibit uncontrolled growth ([@bb0285; @bb0485; @bb0710]). In laser-induced glaucoma and retinal injury, *ivit* BMSCs also migrate into the retina ([@bb0655]) where they continue to proliferate ([@bb0725]). After subretinal transplantation, NSCs remain immature for at least 7 months, barely proliferate and neither exhibit uncontrolled growth nor oncogenesis, but they do migrate from the injection site within the subretinal space ([@bb0465; @bb0420]). By contrast, after *ivit* transplantation, NSCs either attach to the retina and lens where they remain ([@bb0300]), or integrate into the inner retinal layers ([@bb0215]). ESC-derived RPE cells transplanted into the subretinal space of Royal College of Surgeon (RCS) rats (which spontaneously undergo RPE and subsequent photoreceptor degeneration) survive for over 200 days, preserve visual function with evidence of neither teratoma formation ([@bb0415]) nor proliferation ([@bb0720]). Reactive retinal gliosis rather than penetration of the internal limiting membrane is proposed as a major limitation to retinal integration of ESC after *ivit* implantation ([@bb0050]); whilst after subretinal grafting cell migration is more extensive ([@bb0050; @bb0355]) yet still hindered by the outer limiting membrane ([@bb0730]).

Immunological acceptance of stem cells transplanted into the eye {#s0020}
================================================================

The vitreous cavity, like the anterior chamber of the eye, is an immunoprivileged environment ([@bb0275]) and thus amenable to cell transplantation. MSC fail to trigger an immune response when challenged with allogeneic lymphocytes and MSC-derived factors inhibit the proliferation of immunological cells ([@bb0345; @bb0650]). These immunosuppressive/immunomodulatory actions of BMSC have led to Phase I ([@bb0375]), Phase II ([@bb0800]) and Phase III ([@bb0455]) clinical trials for the treatment of steroid refractory graft-versus-host disease. ADSCs suppress the immune system with the same efficacy as BMSC in vitro ([@bb0590]) and increase the survival rate of transplants in animal models of graft versus host disease ([@bb0755]), whereas DPSC are as efficient as BMSC in the suppression of T cell proliferation in vitro ([@bb0585]). Thus, the failure of the host to launch immune reactions after *ivit*/subretinal implantation of MSC is probably explained by both the immune privileged status of these sites and the immunosuppressive properties of MSC. For example, immunosuppression is not required and adverse effects are not recorded after human BMSC ([@bb0285; @bb0390; @bb0710])/ADSC ([@bb0225])/rodent DPSC ([@bb0470]) transplantation into the eye. Equally, although not immunosuppressive, iPSC derived from the somatic cells of the recipient carry the same histocompatibility antigens and do not require immunosuppression after transplantation. By contrast, ESCs/NSCs require immunosuppression when transplanted into the CNS in animals and, since autologous transplantation is not possible, immunosuppression is required in NSC-based treatment ([@bb0145; @bb0440; @bb0635; @bb0420]). Indeed, NSC transplantation into the subretinal space requires daily immunosuppressive treatment with cyclosporine A and dexamethasone ([@bb0465]). When transplanted into the vitreous without immunosuppression, NSCs are detected in just 50% of transplanted eyes 32 days after grafting ([@bb0215]) suggesting that the immunoprivileged environment of the vitreous does not sustain survival of NSC. ESC-derived RPE cells are one of the first ESC based therapies to be used in humans and early reports of subretinal transplantation as a treatment for AMD confirm their safety, although patients require immunosuppression throughout ([@bb0635]).

Therapeutic potential of stem cell replacement therapies {#s0025}
========================================================

NSC {#s0065}
---

NSC transplantation is beneficial to recovery in a range of CNS injury models, including retinal degeneration ([@bb0465]), SCI ([@bb0435; @bb0010; @bb0440]), stroke ([@bb0270]) and TBI ([@bb0615]), although in many cases, it is unclear if the improved functional recovery observed is attributable to replacement of lost cells and/or trophic support of surviving cells.

For example, when transplanted into injured CNS sites such as those of SCI and TBI, NSCs differentiate into neurons and glia ([@bb0615; @bb0270; @bb0145; @bb0460; @bb0010; @bb0440]), replacing lost cells and providing trophic support for damaged endogenous neurons ([@bb0435]). NSC differentiation is greatly enhanced by containment in a matrix loaded with multiple growth factors ([@bb0440]) and treatment with specific differentiation factors ([@bb0090]). In these instances, functional recovery is attributed to the generation of new NSC-derived neurons that directly integrate into the host neuronal circuitry ([@bb0460; @bb0010]) and not to the paracrine mediated axon regeneration and neuroprotection characteristic of MSC treatment.

Despite recent success with NSC in other CNS injury models, few studies have shown the same effect in the eye. In rats, *ivit* transplantation of NSC after optic neuropathy induced by elevated intraocular pressure does not improve retinal function, despite neuronal differentiation and integration into inner retinal layers ([@bb0215]). A similar study using mice lacking RGC (induced by removal of the superior colliculus) showed that NSCs integrate into the retina but sparsely form βIII-tubulin^+^ mature neurons and do not form functional RGC ([@bb0480]). Re-innervation of central targets by the axons of replacement RGC is not yet possible and there is no evidence to suggest that regeneration of stem cell-derived RGC axons along the optic nerve occurs. Indeed, more success has been seen in RCS rats in which the retinal degeneration is of the photoreceptors rather than the RGC ([@bb0465]). Subretinal transplantation of NSC protects photoreceptors from death in RCS rats ([@bb0465]) by their phagocytosis of photoreceptor outer segments, a role usually restricted to RPE cells which, in RCS rats, are dysfunctional ([@bb0140]). Although a paracrine effect (i.e. secretion of NTF) has been suggested to mediate the effects of NSC in the retina, studies have only demonstrated this when NSCs are genetically modified (e.g. to secrete CNTF ([@bb0300])). The limited number of studies published on NSC in the eye suggests that this stem cell is currently not useful for replacement of RGC, however, functional replacement of photoreceptors by NSC is more plausible because of their short synaptic distances. Despite this, integration of NSC into the outer nuclear layer (ONL) is not followed by differentiation into calbindin^+^/rhodopsin^+^ mature photoreceptors ([@bb0520]) and subretinal transplanted NSCs protect, rather than replace photoreceptors ([@bb0465; @bb0300]).

BMSC {#s0070}
----

In vitro neuronal differentiation and neuritogenesis of BMSC are probably artefacts resulting from cell shrinkage and toxicity yielding morphologies characteristic of neurons ([@bb0430; @bb0515]). Undifferentiated BMSCs co-express many functional ion channels ([@bb0395]) as well as mature neuronal and glial markers, such as βIII-tubulin and GFAP, respectively ([@bb0320; @bb0690]) making successful phenotypic differentiation difficult to detect. The ability of BMSC to differentiate into neurons and replace those lost from injury is rarely reported in vivo ([@bb0715]). Their transplantation into the injury site after SCI promotes functional recovery without any evidence of neuronal replacement by BMSC differentiation ([@bb0310]).

In the eye, transplantation of BMSC into the vitreous after experimentally-induced glaucoma and optic nerve transection shows no evidence of their differentiation into mature retinal cells, despite some integration into the retina ([@bb0770; @bb0285; @bb0390]). After transplantation into the subretinal space in RCS rats and mouse models of retinitis pigmentosa, BMSCs sparsely differentiate into cells with neuron and glia characteristics, but not mature photoreceptors or RPE cells ([@bb0780; @bb0710]) and a protective effect on endogenous photoreceptors and RPE cells is observed ([@bb0035; @bb0425]).

ADSC {#s0075}
----

There is conflicting evidence for the differentiation of ADSC into neurons in vivo and in vitro ([@bb0025; @bb0760]). BDNF/retinoic acid treatments induce the differentiation of ADSC into functional neurons, confirmed by patch clamp analysis and the expression of phenotypic neuronal markers ([@bb0025]). The ADSC-derived neuronal phenotypes demonstrated in this and other studies ([@bb0760]) is only transient with de-differentiation occurring after withdrawal of the differentiation-inducing medium ([@bb0760]), explaining why ADSC-derived neurons are rarely seen in vivo after transplantation in animal models of stroke ([@bb0315]). Both studies ([@bb0315; @bb0760]) concluded that cerebrospinal fluid and CNS neuropil do not sustain neuronal differentiation of ADSC. By contrast, ADSCs pre-differentiated into NG2^+^/S100^+^ glia survive for up to 8 weeks after transplantation into rodent SCI sites ([@bb0030]) and thus, like other MSC, probably differentiate preferentially into glia in vivo ([@bb0090; @bb0125; @bb0385]).

ADSCs survive for up to 90 days in the vitreous cavity after transplantation although their fate has not been studied ([@bb0225]). Interestingly, ADSC transplanted into the vitreous cavity of mouse models of diabetic retinopathy preferentially differentiate into pericytes, associating with and conserving the retinal vasculature, suggesting a unique role for ADSC in treating diabetic retinopathy ([@bb0485]). The failure of ADSC to integrate into the retinal layers diminishes their potential for RGC and photoreceptor replacement ([@bb0485]).

DPSC {#s0080}
----

DPSC differentiate into functionally active neurons in vitro ([@bb0040; @bb0330]) and, when transplanted, integrate and survive in injured rat brain tissue for at least 4 weeks ([@bb0325; @bb0180]). Other studies demonstrate that, although DPSC-derived neurons express neuronal phenotypic markers, they neither generate action potentials nor form functional neuronal networks ([@bb0795]). Like BMSC, they constitutively express mature neuronal and glial phenotypic markers even in an undifferentiated state and this may explain the contradictions in the literature if these characteristics are taken as a read out of successful differentiation ([@bb0320; @bb0690]). In vivo, transplantation of DPSC into rat SCI lesion sites leads to functional recovery yet only glial, not neuronal, differentiation is observed ([@bb0620]), suggesting that differentiation of DPSC into neurons is possible in vitro but currently has not yet been realised in vivo. After transplantation into the vitreous, DPSC do not differentiate into neurons and fail to integrate into the retina ([@bb0470]), limiting their potential as a cell replacement therapy.

ESC/iPSC {#s0030}
--------

The greatest potential for cell replacement has been seen with ESC/iPSC, which can be successfully predifferentiated prior to transplantation in the eye, with the most success demonstrated in RPE/photoreceptor replacement for AMD ([Fig. 2](#f0010){ref-type="fig"}).

ESC can be directed towards a retinal phenotype with developmental induction signals including bone morphogenetic protein (BMP) antagonists ([@bb0350]), Wnt inhibition ([@bb0740]) and insulin-like growth factor (IGF) treatment ([@bb0575]). Accordingly, 30% of ESC/iPSC differentiate into retinal progenitors ([@bb0260]), a number that increases to 80% for both ESC ([@bb0360]) and iPSC ([@bb0705]) by incorporating BMP/Wnt inhibition with IGF and FGF treatments. These ESC/iPSC-derived retinal progenitors successfully mature into photoreceptors as well as RPE cells and integrate into retinal explants after co-culture with adult retina/retinal neurons ([@bb0540]) or after the addition of a cocktail of small molecules ([@bb0550]). Comparisons of the gene expression profiles of ESC-derived retinal cells with primary developing foetal retinal cells using microarray analysis show them to be highly conserved between the two cell sources throughout development ([@bb0365]).

ESC-derived retinal progenitors, primed to form neuronal retina rather than RPE using FGF, successfully differentiate into photoreceptors ([@bb0230]), integrate into the ONL ([@bb0355]) and survive for over 3 months in the subretinal space of non-immunosuppressed mice with an intact blood--retinal barrier, with integration more significant when the retina is injured ([@bb0230]). iPSC-derived photoreceptors transplanted into the subretinal space integrate into the ONL and increase retinal function as determined by electroretinogram (ERG) ([@bb0705]). Transplantation of ESC-derived photoreceptors into the vitreous of newborn mice leads to their correct topographic integration into all the layers of the retina, i.e. ESC-derived photoreceptors move to the ONL, whereas ESC-derived amacrine cells and RGC-like cells migrate to the inner nuclear layer/ganglion cell layer ([@bb0355; @bb0805]). However, integration is only possible up to 48 h after birth, corroborating reports that in adult rats, *ivit* ESC-derived cells fail to integrate into the retina ([@bb0050]).

Both mouse ([@bb0175]) and human ([@bb0510]) ESC can be induced to form a complete topographically organized retina, including the RPE. Developing photoreceptors, isolated from ESC-derived ex vivo retina, integrate after transplantation into mouse models of retinal degeneration ([@bb0210]). These findings have been replicated using iPSC showing the formation of a synaptically connected stratified retina ([@bb0580]).

ESC/iPSC can be induced to predominantly differentiate into RPE cells using similar protocols as above, but with the omission/antagonism of FGF to bias the generation of RPE cells over neural retina ([@bb0500; @bb0545]). These ESC/iPSC-derived RPE cells phagocytise photoreceptor outer segments ([@bb0095]) and preserve retinal function in the RCS rats ([@bb0720; @bb0100]). A study comparing adult human ESC-derived RPE with foetal human RPE demonstrated a strong correlation in their gene expression profiles. However, iPSC-derived RPE have a distinct gene expression profile, indicating potential differences between ESC-derived retinal cells and iPSC-derived retinal cells ([@bb0400]).

Subretinal transplantation of ESC/iPSC-derived RPE in cases of AMD requires approximately 60,000 cells ([@bb0070]) to restore RPE-mediated recycling of photoreceptor outer segments. In contrast to photoreceptor replacement, in this instance significant migration, integration and synaptogenesis is not required to achieve functional efficacy. Its effectiveness is already proven by the fact that current surgical intervention relies on the same principles i.e. translocating the macula to an adjacent, healthy portion of RPE ([@bb0150]). These attributes have led to the first clinical trial transplanting ESC-derived RPE cells in patients with AMD ([@bb0635]).

ESCs/iPSCs are able to differentiate into RGC and, during the formation of ESC-/iPSC-derived retina ex vivo, RGCs are the first cells to develop which mimic normal retinal development ([@bb0175; @bb0510; @bb0580]). The yield of RGC is enhanced by transfection of the stem cells with genes regulating RGC development, namely *math5* and *sox4* ([@bb0280]). Similar to ESC/iPSC-derived photoreceptors integrating into the ONL, transplanted adult rat RGCs integrate and survive in the ganglion cell layer ([@bb0245]) but, unlike photoreceptors, the long distances over which RGC axons must regenerate to re-innervate central targets is unachievable ([@bb0685]).

Therapeutic potential of stem cell trophic support ([Fig. 1](#f0005){ref-type="fig"}; [Table 2](#t0010){ref-type="table"}) {#s0035}
==========================================================================================================================

NSC {#s0085}
---

When transplanted into SCI lesion sites, NSCs increase the expression of NGF, BDNF, NT-3 and GDNF within the lesion site ([@bb0220; @bb0240]) and promote axonal sprouting ([@bb0435]). However, the trophic support provided by undifferentiated NSC only minimally restores function compared to when they are induced to differentiate down a neuronal lineage before or after transplantation into SCI sites ([@bb0090; @bb0010; @bb0220; @bb0240]). In the eye, as stated above, *ivit* NSCs transplanted into the vitreous fail to improve function in models of elevated intraocular pressure-induced RGC loss ([@bb0215]) and axotomy ([@bb0195]) and only show neuroprotective efficacy when transfected to secrete CNTF. However, transplantation was made four weeks post-injury, so that it cannot be ruled out that NSC may be able to have a paracrine-mediated neuroprotective effect on RGC if they were transplanted at the time of injury when injured RGCs are most amenable to neuroprotective strategies. Nonetheless, after subretinal transplantation of NSC into RCS rats, rather than replaced, photoreceptors are protected against death by NSC-directed phagocytosis of photoreceptor outer segments ([@bb0140]) and induction of CNTF expression by Müller glia ([@bb0420]).

BMSC {#s0090}
----

The neurotrophic secretome of BMSC, which includes NGF, BDNF, NT-3, NT4/5, CNTF, GDNF and PDGF is widely documented ([@bb0165; @bb0120; @bb0735; @bb0205; @bb0620; @bb0290; @bb0470; @bb0475]) and places them as a candidate cellular therapy to combat ocular neurodegeneration. BMSC-mediated neuroprotection of RGC is reported to be mediated by PDGF ([@bb0290]), whilst other studies have shown that BMSC-induced RGC neuroprotection and axon/neurite growth is mediated by NGF, BDNF and NT-3 ([@bb0470]). The importance of BMSC-derived NTF for retinal neuron survival is confirmed by using TrK and PDGFR inhibitors which significantly diminish the RGC neuroprotection and/or neurite growth effects elicited by BMSC ([@bb0290; @bb0470; @bb0475]). The vitreous does not permit the differentiation of BMSC into neurons ([@bb0250]). Nonetheless, *ivit* transplanted BMSCs secrete diffusible NTF, BDNF and NT-3 ([@bb0470]), directly protecting RGC from death in animal models of glaucoma ([@bb0770; @bb0285]) and optic nerve transection ([@bb0390; @bb0470]), and can also be indirectly effective by inducing Müller cell NTF production ([@bb0380]). Interestingly, BMSC also promote the regeneration of RGC axons after optic nerve crush ([@bb0470]), probably through the same NTF-mediated mechanisms ([@bb0065]). Subretinal and *ivit* BMSC transplantation in RCS rats and mouse models of retinitis pigmentosa significantly improves retinal function by preserving photoreceptor and RPE cell viability ([@bb0035; @bb0425; @bb0710]) and, although the underlying observations remain equivocal, a role for the NTF secretome in promoting cell survival is a likely explanation.

ADSC {#s0095}
----

ADSCs express NGF, BDNF, NT-3, GDNF, VEGF and PDGF ([@bb0305; @bb0815; @bb0475]), with titres of BDNF and vascular endothelial growth factor (VEGF) being significantly higher than those secreted by BMSC ([@bb0815]). Despite this, ADSCs are relatively untested in the eye but have efficacy as a paracrine-mediated therapy in other CNS animal injury models like SCI ([@bb0030; @bb0815]) and stroke ([@bb0315]). In co-culture, ADSC-derived NTF promote neuroprotection and neuritogenesis of injured RGC, although the effects are not as pronounced as those achieved with BMSC/DPSC ([@bb0475]). In a mouse model of light induced photoreceptor damage, both *ivit* ADSC and ADSC-conditioned medium preserve ONL thickness and the amplitude of the a-wave of the ERG ([@bb0680; @bb0700]). Progranulin, tissue inhibitor of metalloproteinases-1 (TIMP1) and the secreted protein rich in cysteine (SPARC) are the active agents produced by ADSC in vitro and, after *ivit* transplantation, have similar effects to *ivit* ADSC/ADSC conditioned medium. Together, these data suggest that ADSC have therapeutic potential for neurodegenerative conditions through NTF production, with many of the active factors different from those produced by BMSC and DPSC.

DPSC {#s0100}
----

Like other MSCs, DPSCs have an extensive neurotrophic secretome which includes NGF, BDNF, NT-3, GDNF, VEGF and PDGF ([@bb0525; @bb0530; @bb0200; @bb0620; @bb0470; @bb0475]). Interestingly, DPSCs express significantly greater amounts of *ngf*, *bdnf* and *nt-3* mRNA than BMSC ([@bb0620]) and this is true also for the secreted proteins NGF, BDNF and NT-3 ([@bb0470]). DPSC-conditioned medium containing the above factors promotes neurite outgrowth of cortical neurons ([@bb0620]), a neuroblastoma cell line ([@bb0265]) and primary RGC ([@bb0470; @bb0475]) with significantly greater efficacy than BMSC and ADSC-conditioned medium. DPSCs transplanted into mouse hippocampus increase the basal expression levels of many NTF such as CNTF, VEGF, FGF-2 and NGF ([@bb0255]), although it is unknown if the transplanted DPSCs directly express these NTFs and/or indirectly promote the expression of NTFs by neighbouring cells in the surrounding neuropil. DPSC transplantation into rat SCI lesion sites leads to greater functional improvement than BMSC transplantation and, with a lack of observable neuronal differentiation, the evidence strongly suggests a paracrine-mediated mechanism ([@bb0620]). Following either *ivit* transplantation or co-culture with injured RGC, DPSCs secrete NGF, BDNF and NT-3 and promote RGC survival and axon/neurite regeneration; effects which are attenuated by Fc-TrK blockers ([@bb0470; @bb0475]). These neuroprotective/pro-regenerative effects are significantly greater in DPSC transplanted animals compared to BMSC transplanted animals and are correlated with a more favourable neurotrophic secretome by DPSC compared to BMSC ([@bb0470; @bb0475]). Currently, no evidence exists for DPSC-mediated protection of photoreceptors whilst further research into the mechanisms of DPSC-mediated RGC neuroprotection is required.

ESC/iPSC {#s0040}
--------

Unlike MSC, the paracrine potential of ESC/iPSC for treating the injured retina/CNS is as yet unknown. Addition of TrK receptor blockers to ESC cultures perturbs their survival, indicating that neurotrophins are released and active in an autocrine fashion, but further analysis on the secretome is required ([@bb0595]). *ivit* transplantation of ESC-derived photoreceptors promotes the survival of nearby endogenous photoreceptors ([@bb0495]). Similarly it is known that RPE cells secrete VEGF and PEDF, which may further explain how ESC-derived RPE cells protect photoreceptors from death ([@bb0675]).

Conclusions {#s0045}
===========

The use of stem cells has proven potential as a cellular therapy for retinal degenerative conditions through replacement of lost cells in the eye and/or the release of growth factors into damaged neuropil. However, the mechanism of action as well as the efficacy of the cellular therapy vary between different stem cells and can contrast greatly with what is seen in other models of CNS injury. ESCs/iPSCs have shown potential as a source of retinal cells for replacement of particularly photoreceptors and RPE, but their possible paracrine action is currently not known. Although the potential trophic properties are still not fully understood, NSCs have proven impressive cell replacement properties in other CNS regions and these faculties may be enhanced, optimised and refined by pre-treatment with selected growth/inducible factors leading to their formulation as an effective cell replacement therapy in the retina. By contrast the dominant mechanism by which MSCs restore lost retinal function appears to be paracrine-mediated, which offers the potential for their use to provide continuous delivery of multiple growth factors to provide direct trophic support for neurons in the degenerate retina and to stimulate glia to indirectly help effect neural repair. The non-invasive, non-tumorigenic, immunosuppressive and trophic characteristics of MSC, along with the relatively ease of access from their diverse adult tissue sources, circumvent moral and ethical dilemmas and make the autologous and allogeneic intra-ocular implantation of MSC a promising paracrine-mediated therapy for the diseased eye.
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![A schematic diagram showing the proposed mechanism by which MSCs exert their neurotrophic effects on the injured CNS, including the retina, through secretion of NGF, BDNF, NT-3, CNTF GDNF, VEGF, FGF and PDGF which engage TrK A, B and C, CNTFα, GFRα, VEGFR, FGFR1 and PDGFR receptors, respectively, leading to the activation of intracellular pathways for axon growth, axon growth disinhibition and neuroprotection, accounting for the functional recovery seen in animals receiving MSC transplants after CNS/retinal injury. Some ligand-receptor interactions lead to the activation of the same signalling pathways (abbreviations: BAD, bcl-2-associated death promoter; Bcl2, B-cell lymphoma 2; FGFR1, fibroblasts growth factor receptor 1; FRS2, fibroblast growth factor receptor substrate 2; GFRα, GDNF family receptor alpha; Grb2, growth factor receptor-bound protein 2; GSK-3β, glycogen synthase kinase-3β; IAPS, inhibitor of apoptosis; MAPK, mitogen-activated protein kinase; Mek, mitogen-activated protein kinase; PDK, phosphoinositide-dependant kinase; PKC, protein kinase C; PLCγ, phospholipase C-gamma).](gr1){#f0005}

![A diagram showing the proposed way in which ESC/iPSC-derived RPE and photoreceptors can be used to treat AMD/photoreceptor degeneration. The left panel shows a rat retina immunohistochemically stained for cone annexin (cone photoreceptor marker; green), Brn3a (RGC marker; red) and DAPI (nuclear marker; blue) with the individual layers labelled (scale bar: 100 μm). On the right, RPE is represented together with photoreceptor loss in AMD and the potential for cell replacement in preventing visual decline and restoring vision.](gr2){#f0010}

###### 

Current clinical trials that test the safety and efficacy of stem cell transplantation for the treatment of degenerative eye disease. Further details found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov){#ir0010}.

  Treatment                                   Disease                                           Stage                                            No. of subjects   Estimated completion date   Outcome                                                                                       Clinicaltrials.gov identifier
  ------------------------------------------- ------------------------------------------------- ------------------------------------------------ ----------------- --------------------------- --------------------------------------------------------------------------------------------- -------------------------------
  Intravitreal BMSC                           AMD, glaucoma                                     Recruiting participants                          300               Aug 2017                    Visual acuity, visual field                                                                   NCT01920867
  Intravitreal BMSC                           AMD, diabetic retinopathy, retinitis pigmentosa   Recruiting participants ([@bb0570])              15                Dec 2015                    Incidence and severity of adverse events                                                      NCT01736059
  Intravitreal BMSC                           Retinitis pigmentosa                              Recruiting participants                          10                Aug 2016                    Visual acuity, quality of life, visual field, ERG, VEP, colour vision, contrast sensitivity   NCT02280135
  Intravitreal BMSC                           Glaucoma                                          Recruiting participants                          10                Dec 2016                    Incidence and severity of adverse events, visual acuity, visual field, OCT, ERG               NCT02330978
  Intravitreal BMSC                           Retinitis pigmentosa                              Completed ([@bb0660])                            50                June 2013                   Visual acuity                                                                                 NCT01560715
  Intravitreal BMSC                           Ischemic retinopathy                              Recruiting participants                          30                Jan 2014                    Size of foveal avascular zone                                                                 NCT01518842
  Intravitreal BMSC                           AMD                                               Recruiting participants                          1                 June 2015                   Incidence and severity of adverse events                                                      NCT02016508
  Intravitreal BMSC                           AMD, Stargardt\'s macular dystrophy               Recruiting participants                          10                Dec 2015                    Visual acuity                                                                                 NCT01518127
  Intravenous bone marrow mononuclear cells   Optic atrophy                                     Recruiting participants                          24                July 2016                   Visual function, reduction in optic nerve degeneration                                        NCT01834079
  Intravitreal AMSC                           Dry AMD                                           Recruiting participants                          100               June 2016                   Incidence and severity of adverse events, visual acuity                                       NCT02024269
  Subretinal ESC-derived RPE                  Dry AMD                                           Recruiting participants                          12                April 2016                  Visual acuity, ERG, OCT                                                                       NCT01674829
  Subretinal ESC-derived RPE                  AMD                                               Pre-recruitment                                  10                June 2017                   Incidence and severity of adverse events, visual acuity                                       NCT01691261
  Subretinal ESC-derived RPE                  Stargardt\'s macular dystrophy                    Recruiting participants ([@bb0635]; [@bb0640])   16                Dec 2014                    Incidence and severity of adverse events                                                      NCT01345006
  Subretinal ESC-derived RPE                  Dry AMD                                           Recruiting participants [@bb0640]                16                Dec 2014                    Incidence and severity of adverse events                                                      NCT01344993

###### 

NTF known to be secreted by NSC, BMSC, ADSC and DPSC. NTF secretion by ESC/iPSC is currently unreported.

  Stem cells   Neurotrophic factor secretion profile
  ------------ ----------------------------------------------------------------------------------------------------------------------------------------------
  NSC          NGF, BDNF, NT-3, GDNF ([@bb0435]); ([@bb0220]); ([@bb0240])
  BMSC         NGF, BDNF, NT-3, NT-4/5, CNTF, GDNF, PDGF ([@bb0165]); ([@bb0120]); ([@bb0735]); ([@bb0205]); ([@bb0620]); ([@bb0290]); ([@bb0470; @bb0475])
  ADSC         NGF, BDNF, NT-3, GDNF, VEGF, Progranulin, SPARC ([@bb0305]); ([@bb0680]); ([@bb0815]); ([@bb0700]); ([@bb0475])
  DPSC         NGF, BDNF, NT-3, CNTF, GDNF, VEGF, FGF-2 ([@bb0525; @bb0530]); ([@bb0255]); ([@bb0200]); ([@bb0620]); ([@bb0470; @bb0475])
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